Is BPC-157 + KPV approved as a medicine, and where?

The regulatory review of BPC-157 + KPV is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.

What is BPC-157 + KPV studied for?

Research has examined Component-level GI / anti-inflammatory preclinical research (see linked monographs). Being studied for an area does not mean it is proven or approved for it.

Does BPC-157 + KPV have human clinical trials?

The evidence review of BPC-157 + KPV is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Index by category›

Peptide Blends

BPC-157 + KPV

Name: BPC-157 + KPV
Creator: PeptideInfo Wiki editorial collective
Published: 2026-10-07

BPC-157 KPV gut stack; Gut stack; BPC KPV blend; KPV + BPC-157

3 min read · Updated October 7, 2026 · 11 references

Curated by PeptideInfo Wikilast reviewed October 7, 2026how we verify

In brief · TL;DR

Source record — verification pending

Vendor two-peptide blend (BPC-157 + KPV), not a drug substance. No controlled combo data. Not the same as KLOW (four peptides). Do not transfer K(D)PT UC trial data to KPV. No blend dose is established.

Evidence: Catalog coverage only; independent identity, evidence and regulatory review is still pending.

Trade blend / co-lyophilisate of two peptides — not a new molecule and not a pharmacopoeial standard
No controlled study of BPC-157 + KPV together was identified (2026-10-07 dossier); PubMed BPC+KPV hit PMID 42752426 is compounding overview, not combo efficacy
Explicitly not KLOW — KLOW = GHK-Cu + KPV + BPC-157 + TB-500 (four peptides)
K(D)PT (PMID 28092306 Phase IIa UC) is a different tripeptide analogue — do not transfer those data to KPV or this blend
See component monographs for evidence; do not infer blend synergy from component literature

↓ Read the full referenced entry below

BPC-157 + KPV is a commercial name for a two-peptide vendor mixture — not a new covalent molecule. No controlled combination study (human, animal, or in vitro) was identified; the only PubMed hit for BPC-157 AND KPV is a compounding-industry overview, not combo efficacy. Evidence is component-wise only.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents7

Editorial review pending — noindex

This page remains under independent editorial review (reviewPending). It is visible in the wiki but noindexed. Editorial lane: scope-review-blend.

No controlled combination data

In the reviewed 2026-10-07 dossier, no controlled study of BPC-157 + KPV as a fixed blend was identified. Claims of synergy, a “gut healing stack protocol,” or a clinical stack dose lack primary literature support. Evidence, where it exists, is component-wise only.

Section 1 of 7What this blend name means

What this blend name means

BPC-157 + KPV (often marketed as a “gut stack”) is a commercial name for a two-peptide mixture — typically co-lyophilised BPC-157 plus KPV in one vial or sold as a paired stack. It is not a covalent conjugate, not a unique API, and not an approved medicine.

Section 2 of 7How it differs from neighbouring blends

How it differs from neighbouring blends

Name	Typical labelled components	Peptide count
This page (BPC-157 + KPV)	BPC-157 + KPV	Two
GLOW	GHK-Cu + BPC-157 + TB-500	Three
KLOW	GHK-Cu + KPV + BPC-157 + TB-500	Four
Wolverine blend	BPC-157 + TB-500	Two (different pair)

Explicitly: this stack is not KLOW. Shared marketing language about “gut” or “healing” does not make the products chemically or clinically equivalent.

Section 3 of 7Component evidence (what may be said)

Component evidence (what may be said)

BPC-157

See the BPC-157 monograph. Literature is predominantly preclinical GI/healing work. There is no robust published RCT establishing a GI indication; human evidence remains sparse/anecdotal and must not be transferred into a blend synergy claim. Not an approved medicine.

KPV

See the KPV monograph. Preclinical anti-inflammatory / colitis-model findings exist (e.g. Dalmasso PMID 18061177; Getting PMID 12750433). No well-established human RCT for KPV alone supports a clinical gut-stack claim.

Alias trap — K(D)PT ≠ KPV

K(D)PT (PMID 28092306 (opens in a new tab), Phase IIa ulcerative colitis) is a different tripeptide analogue. Those clinical data must not be attributed to KPV or to the BPC-157 + KPV blend.

Section 4 of 7Combination literature search

Combination literature search

PubMed query "BPC-157" AND KPV (dossier cut 2026-10-07) returned one hit: PMID 42752426 (opens in a new tab) — a pharmacy compounding / PCAC recommendations overview, not an efficacy or interaction study of the pair. No ClinicalTrials.gov intervention study of the combination was identified in that pass.

Section 5 of 7Claims vs evidence

Claims vs evidence

Claim	Assessment
Two-peptide vendor blend exists as a catalog name	Supported (market / gap list) — not medical effect
Controlled study of BPC-157 + KPV together	Missing
Synergistic gut healing	Unsupported
Stack = sum of component preclinical literature	Qualified hypothesis only — hypothesis ≠ measured combo result
K(D)PT UC data = KPV or this blend	False
Same product as KLOW	False
Approved / dose established	False

Section 6 of 7Related pages

BPC-157 — component
KPV — component
KLOW — four-peptide blend that includes KPV + BPC-157 plus GHK-Cu + TB-500
GLOW — three-peptide core without KPV
Wolverine blend — BPC-157 + TB-500

Section 7 of 7What this page intentionally omits

What this page intentionally omits

Any blend dose, reconstitution, or “gut protocol”
Synergy or superiority claims versus components or versus KLOW
Transfer of K(D)PT clinical UC results to KPV

References11

References

1.
Synthetic Peptides in Pharmacy Compounding — PCAC recommendations overview (only PubMed BPC+KPV hit; not combo efficacy) — International Journal of Pharmaceutical Compounding, 2026. source
2.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Dalmasso G, et al., 2008. source
3.
α-MSH and C-terminal KPV in inflammation models — Getting SJ, et al., 2003. source
4.
Nanoparticle-mediated delivery of KPV in colitis models — Xiao B, et al., 2017. source
5.
KPV and fine-dust keratinocyte inflammation (preclinical) — 2025. source
6.
K(D)PT Phase IIa ulcerative colitis — DIFFERENT tripeptide; not KPV — 2017. source
7.
PeptideInfo — BPC-157 source
8.
PeptideInfo — KPV source
9.
PeptideInfo — KLOW source
10.
PeptideInfo — GLOW source
11.
PeptideInfo — Wolverine blend source

Frequently asked questions4

Frequently asked questions

What is BPC-157 + KPV?: BPC-157 + KPV is a commercial name for a two-peptide vendor mixture — not a new covalent molecule. No controlled combination study (human, animal, or in vitro) was identified; the only PubMed hit for BPC-157 AND KPV is a compounding-industry overview, not combo efficacy. Evidence is component-wise only.
Is BPC-157 + KPV approved as a medicine, and where?: The regulatory review of BPC-157 + KPV is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.
What is BPC-157 + KPV studied for?: Research has examined Component-level GI / anti-inflammatory preclinical research (see linked monographs). Being studied for an area does not mean it is proven or approved for it.
Does BPC-157 + KPV have human clinical trials?: The evidence review of BPC-157 + KPV is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. The editorial review of BPC-157 + KPV is incomplete. Source-supported findings and remaining uncertainties are stated in the article; review status does not certify approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.

References

Frequently asked questions

Related in Peptide Blends